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Abstract 
DNA polymerase (pol)  is a specialized error-prone polymerase with at least two quite different and 
contrasting cellular roles: to mitigate the genetic consequences of solar UV irradiation, and promote 
somatic hypermutation in the variable regions of immunoglobulin genes. Misregulation and 
mistargeting of pol  can compromise genome integrity. We explored whether the mutational 
signature of pol  could be found in datasets of human somatic mutations derived from normal and 
cancer cells. A substantial excess of single and tandem somatic mutations within known pol  mutable 
motifs was noted in skin cancer as well as in many other types of human cancer, suggesting that somatic 
mutations in A:T bases generated by DNA polymerase  are a common feature of tumorigenesis. 
Another peculiarity of pol mutational signatures, mutations in YCG motifs, led us to speculate that 
error-prone DNA synthesis opposite methylated CpG dinucleotides by misregulated pol  in tumors 
might constitute an additional mechanism of cytosine demethylation in this hypermutable dinucleotide. 
Key words: hypermutation, POLH, mutable motif, DNA lesion bypass, sloppy DNA polymerase, skin 
cancer, gene expression profiles 
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Introduction 
The etiology of cancer lies in changes of genetic programming within the cell. Over the last 
decade, advances in sequencing technologies have potentiated the sequencing of whole genomes of 
both liquid and solid cancers (as well as individual tumor cells) giving birth to the new field of cancer 
genomics. One of the most significant discoveries has been that cancer genomes differ from the 
genomes of normal cells in their immediate vicinity in terms of thousands of newly acquired cancer-
driving and passenger mutations 1-3, in perfect accordance to “mutator” theory of cancer 4, 5. Multiple 
mutagenic processes, instigated by hereditary defects, or driven by intrinsic and environmental 
mutagens, contribute to this “genetic collapse” that changes the identity of cells 6-8. The spectrum of 
genetic changes includes point mutations and other micro-lesions, chromosomal rearrangements and 
copy number changes that can be characteristic of both cancer and tissue type. For example, different 
types of tumor differ strikingly between mouse strains with defective exonucleases of pol  versus pol  
9 or when different members of APOBEC family are expressed, such as activation-induced deaminase 
AID (predominantly liquid tumors) versus APOBEC3B (breast and other solid tumors) in humans 10-12. 
The hereditary lack of mismatch repair and/or exonuclease activity of replicative DNA pols predispose 
to colorectal cancer 13-15; abnormal DNA double strand break repair leads to an increase in incidence 
of breast and ovarian cancer 16; sunlight and defective pol  cause skin cancer 17.  
Normal somatic cells also acquire mutations induced by the abovementioned plethora of factors 
during an individual’s life time, albeit at lower rates than in tumors. For instance, comparison of the 
mutational burden in skin fibroblasts from forearm and hip from the same donors, revealed that the UV-
induced (primarily C:G > T:A and CC:GG > TT:AA changes) and endogenous mutation rates per year in 
exposed skin were more than two-fold higher than that in unexposed areas 18. This is in accord with 
previous studies of somatic mutations in sun-exposed skin 19, 20. Cyclobutane pyrimidine dimers and (6-4) 
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photoproducts are the two major classes of lesion generated in DNA by UVB and UVC irradiation. Bypass 
of UV-induced photoproducts at TT tandem bases by the yeast and human translesion pol  (a member 
of the Y family of specialized DNA polymerases) is relatively accurate; this polymerase inserts the 
complementary AA nucleotides into the newly synthesized DNA in more than 99% of bypass events 
(measured using steady-state kinetic assays), thereby bypassing the lesion and suppressing the 
mutagenic effect of UV-induced DNA damage 21. 
DNA pol  copies undamaged DNA with a lower fidelity than most DNA-directed polymerases 
with an average base-substitution error rate of 3.5 x 10-2 22-24. Germline mutations in the gene (POLH) 
encoding DNA pol  result in XPV, a variant type of xeroderma pigmentosum 25. Analysis of somatic 
mutations has suggested that transcription-coupled repair systems and DNA pol  are involved in the 
control of generation of somatic mutations in normal skin cells 18, 20. It has also been noted that the ‘pol 
 mutational signature’ (Signature 9; http://cancer.sanger.ac.uk/cosmic/signatures) occurs in chronic 
lymphocytic leukemia and malignant B-cell lymphoma genomes 6, 26, 27. “Signature 9” is characterized by 
a pattern of mutations that has been attributed to pol η (see the Discussion section for details) recruited 
for the repair of DNA damaged by AID during somatic hypermutation in immunoglobulin genes 28-30. The 
mutable motif of pol , the short motif WA/TW (W=A or T) was delineated in the context of somatic 
hypermutations and in vitro systems 22, 23). We detected this signature in follicular lymphomas, but only significant in 5’UTR regions {Rogozin, 
2016 #380, 29. A recent study suggested that pol  may cause somatic mutations in lymphoid cells 31; most of 
the characteristic clustered mutations were found in promoters, as with AID-initiated somatic 
hypermutation. In solid tumors, however, somatic mutations are likely to be associated with the other 
factors, including exogenous exposures, UV radiation or alcohol consumption 31. 
In this paper, we have studied the possible involvement of pol  in the generation of somatic 
mutations in skin cancer, other cancers and in normal cells. A highly significant correlation between pol 
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 mutable motifs and somatic mutations in skin cancer cells was found. However, this correlation was 
not observed in normal skin samples. In addition to this, we also found traces of pol  mutagenesis in 
various other cancers. Taken together with the results of expression analysis, our study suggests the 
widespread participation of pol  in mutagenesis in cancer cells. 
 
Results 
Analysis of single and tandem somatic mutations found in normal skin 
samples 
The starting point of our study was an analysis of single and tandem mutations in normal skin 
samples because of the known role of various DNA pols in the generation of somatic mutations in 
vigorously proliferating and exposed to environmental insults normal skin cells 9, 18, 20. The majority of 
tandem double mutations are likely to be caused by the bypass of UV photoproducts formed between 
two pyrimidine residues, which is expected to be a significant feature of the mutational signature of pol 
 32-34. The dinucleotide mutabilities of CC, CT, TC and TT are actually strikingly different (Figure 1). TT 
dinucleotides have the lowest frequency of double and single mutations, consistent with the suggested 
antimutagenic property (see the Introduction section) of pol  while bypassing TT dimers. CC 
dinucleotides are extremely susceptible to changes (mostly transitions) and yielded the largest number 
of tandem double mutations (Figure 1).  
Single mutations demonstrated a different propensity: the most frequently mutated are CG 
dinucleotides (Figure 1). It is well known that the motif YCG/CGR is hypermutated in human normal and 
cancer skin cells 18, 35. CC dinucleotides were also found to be highly mutable although the frequency of 
mutation was lower than for CG dinucleotides (Figure 1). The third highest ranked mutable dinucleotide 
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was TC/GA. If we assume that pol  is responsible for the inaccurate bypass of dimers in CC, TC and CT 
dinucleotides, one would expect there to be an excess of single mutations in TC and CT dinucleotides (T 
is processed correctly and mutations arise while synthesizing past C nucleotides). We analyzed the 
excess of single mutations in TC/GA and CT/AG (positions of studied mutations are underlined). 
Examination of the DNA sequence context of mutations in these motifs showed that there was indeed a 
significant excess of substitutions (Table 1). The analysis was performed as described previously 36. In 
brief, we calculated the excess of mutations in specific motifs using the ratio Fm/Fs, where Fm is the 
fraction of mutations observed in the particular motif, and Fs is the frequency of the motif in the 
respective DNA neighborhood (defined as a 120 bp DNA sequence window). A 1.2-fold excess of 
mutations (defined as described in Materials and Methods) in TC/GA and CT/AG dinucleotides was 
detected (Table 1). By contrast, there was no association between mutations and the WA/TW motif, 
associated with predominant errors of pol  when copying undamaged DNA 23, 29, indicating that pol  is 
unlikely to be involved in mutagenesis at undamaged DNA sites in normal skin cells (Table 1). 
 
Analysis of somatic mutations in skin cancer samples 
Analysis of skin cancer cells strongly suggested that somatic mutations overlap with mutable 
motifs expected as a consequence of the error-prone bypass of photoproducts (TC/GA and CT/AG 
motifs) and the synthesis of undamaged DNA (WA/TW motifs) (Table 1). We also performed an analysis 
of two skin cancer subtypes with the highest representation in the COSMIC data set (see Materials and 
Methods), skin cutaneous melanoma and skin adenocarcinoma. A substantial (and significant) excess of 
somatic mutations for the both mutable motifs was found for skin cutaneous melanoma (Table 1) where 
the frequency of UV photoproducts is expected to be high. However, no such excess was found for skin 
adenocarcinoma (Table 1), consistent with the fact that adenocarcinoma initiates in the glandular cells 
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that are located deep inside or even under skin tissues, where no elevated frequency of UV 
photoproducts and mutations caused by DNA pol  in pyrimidine dinucleotides is to be expected. 
 
Analysis of somatic mutations in cancers other than skin 
Previously, we found a signature of pol  (WA/TW) in follicular lymphoma which was significant 
only in 5’UTR regions (P-value = 0.01) 36. Thus, it was suggested that a somatic mutational process 
operates in these regions in the “standard immunoglobulin mode” (significant correlation of mutation 
context with WRCH/DGYW and WA/TW mutable motifs, R = G/A, Y = C/T, D=A/T/G). The 5’UTR regions 
are known to be preferentially targeted by deaminases in actively transcribed genes 37, 38. This is 
consistent with earlier studies that suggested that pol  may be mutagenic in chronic lymphocytic 
leukemia and malignant B-cell lymphoma genomes 39. However, a more careful analysis of somatic 
mutations associated with pol  in follicular lymphoma suggests that this process is associated with 
translocations of the BCL2 gene with immunoglobulin genes, a characteristic feature of follicular 
lymphoma 40. Specifically, a detailed analysis of pol  mutability suggested that a substantial proportion 
(24%) of mutated 5’UTR WA/TW motifs occurred within the BCL2 gene (19 out of 28 mutations at A:T 
bases). After we removed mutations that were identified within the BCL2 5’UTR region (near the 
translocation breakpoint), the correlation became insignificant (P-value = 0.11, 60 mutations in WA/TW 
motifs out of 116 mutations at A:T bases) 27. This is one example of how a single mutation hotspot (in 
this case resulting from a translocation) is able to skew the results of the whole exome analysis, yielding 
misleading results. 
Such discrepancies in results before and after elimination of somatic mutations associated with 
translocation events prompted us to analyze the pol  mutable motifs in different (sub)types of cancer. 
We did not find any significant excess of somatic mutations in WA/TW motifs in all types of blood cancer 
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merged together (Table 2). However, we did find such an excess in chronic lymphocytic leukemia and 
GCB lymphomas (subtypes of blood cancer) (Table 2), whereas no significant excess was found for acute 
myeloid leukemia (Table 2). This suggests that pol  may be mutagenic only in some types of blood 
cancer, consistent with the results of previous studies 39. 
We found a significant excess of somatic mutations in WA/TW motifs in 11 out of 14 solid 
tumors from various tissue types (Table 2). Frequent tandem mutations are known to be an intrinsic 
property of DNA pol  when copying undamaged DNA and they have the same context specificity as 
single mutations 23. Although tandem mutations occur much less frequently, we nevertheless found a 
significant excess of tandem mutations in the WA/TW context in 3 out of 8 cancer types (Table 3). A 
significant excess of tandem mutations in lung cancer (Table 3) appears to contradict the absence of any 
association between single somatic mutations and the WA/TW context (Table 2). This may result from 
greater sensitivity of the tandem mutation analysis or from differential representation of lung cancer 
subtypes in datasets of single and tandem mutations. To test the latter possibility, we performed an 
analysis of single mutations in two non-small cell lung cancer subtypes with the highest representation 
in the COSMIC data set, squamous cell carcinoma and adenocarcinoma. No significant association 
between mutations and the WA/TW context was found in lung adenocarcinoma, whereas a significant 
excess (1.3, P = 0.0005) of somatic mutations in the WA/TW context was found for lung squamous cell 
carcinoma suggesting that DNA pol  may be involved in mutagenesis in some lung cancer subtypes but 
not others. It should be noted that many (although not all) lung cancers are associated with cigarette 
smoking and exposure to a wide variety of exogenous mutagens, any of which could influence the 
observed mutational spectrum 6-8, 41. 
Previously, we studied the role of AID in various cancer types and found the AID mutational 
signature to be prevalent in many types of human cancer, suggesting that AID-mediated, CpG 
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methylation-dependent mutagenesis is a common feature of tumorigenesis 36. AID and DNA pol η are 
the two principal mutators involved in the somatic hypermutation of immunoglobulin genes that are 
coupled in the hypermutation machinery: AID is involved in the initiation of somatic hypermutation by 
massive cytosine deamination, whereas DNA pol η in involved in error-prone repair of DNA with the 
resulting lesions 28-30, 42. We proposed to analyze the possible connection between these two enzymes in 
various cancer types using the excess of mutations in mutable motifs as independent variables. We 
found a negative correlation (CC = -0.44) between these two variables (Figure 2) which suggested that 
AID and DNA pol η are even decoupled in cancer-related mutagenesis (though the observed negative 
correlation is marginally significant, P = 0.044, one-tailed test). 
 
Analysis of somatic mutations in various normal tissues and expression 
analysis of Pol  
As a control, we examined the context of somatic mutations in various normal tissues 43 and did 
not find any significant excess of WA/TW mutable motifs (Supplemental Table 1). The size of these 
datasets is limited, but a power analysis (see Materials and Methods) suggested that the absence of any 
significant excess of somatic mutations in WA/TW mutable motifs in normal tissues likely reflects 
genuine biological properties of these samples. 
We also compared the expression levels of the POLH gene (which encodes DNA pol ) in the 
various TCGA cohorts. Quartiles and extrema were calculated for each TCGA cohort selected in the study 
(Supplementary Figure 1). The observed high variability in POLH gene expression suggests that the gene 
is highly expressed only in a subset of TCGA tumor cohorts (Supplementary Figure 1) which is consistent 
with previous studies 44. Specifically, POLH seems to be highly expressed in skin cutaneous melanoma 
(SKCM), consistent with a substantial and significant excess of pol  mutational signatures in this cancer 
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type (Table1). Previous analysis of an additional TCGA cohort with increased POLH expression, namely 
lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), suggested the possible involvement of pol  
because of the presence of its characteristic mutation signature (Signature 9, Supplementary Figure 1, 
39). Notably, subsets of colorectal and uterine cancer (COAD, UCEC), which have been previously 
reported to have no association with polymerase Pol  activity, exhibit reduced POLH gene expression 45, 
46. 
 
Discussion 
A study of mutational signatures left by mutagenic enzymes, and, specifically, by pol , can be 
augmented by investigating the expression profiles of the genes encoding for the enzymes in question 10, 
47. The TCGA atlas represents a comprehensive resource for the investigation of gene expression in the 
context of mutation datasets obtained from cohorts characterized by differing rates of somatic 
mutation. Observed heterogeneity in POLH gene expression within a comprehensive list of TCGA cohorts 
is consistent with previous reports suggesting that POLH activity is tissue- and tumor-specific 45. 
Importantly, an elevated level of POLH expression was observed in tumor cohorts where pol -specific 
mutation signatures were detected. Conversely, a reduced level of POLH expression was observed in 
tumor cohorts where no pol -specific mutation signatures were detected. 
The excess of pol  mutable motifs in chronic lymphocytic leukemia and GCB lymphomas that 
we detected in our work is consistent with the studies of Alexandrov et al. 39 where the pol  signature, 
“Signature 9”, was detected in chronic lymphocytic leukemia and malignant B-cell lymphoma genomes. 
This is a promising result bearing in mind that the mutable motif of pol  (WA/TW) is rather short and 
hence less informative as compared to the AID/APOBEC mutable motifs 27, 29. In general, “Signature 9” is 
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characterized by a pattern of mutations that has been widely attributed to pol η, although a higher 
frequency of T:A > G:C transversions compared to T:A > C:G transitions, although such a pattern has not 
been observed in studies of pol η either in vitro or in vivo 27, 29. Although decomposition into signatures is 
a very useful tool for interpreting mutagenic processes, this approach has certain limitations 27. One of 
them is the heuristic nature of the associations between mutational signatures and molecular 
mechanisms of mutation. In fact, we can never be sure that a given mutational signature can be 
attributed solely and exclusively to one molecular mechanism – indeed, some endogenous or exogenous 
mutational mechanisms may have very similar or even identical signatures 27, 29. 
It should be stressed that important steps toward improving our understanding of the role of pol 
 in mutagenesis in skin cancer have been taken in previous studies, where the impact of transcription-
coupled repair 20and DNA pol  18 in both normal and cancer skin cells were postulated. It should be 
noted that the strand-specificity (a signature of transcription-coupled repair) of mutations induced by 
pol  is well known in the context of the somatic hypermutation of immunoglobulin genes 18, 20, 48, 49. 
Thus, all these studies point to pol  being an important mutagenic factor in normal skin and cancer 
cells. The recent study extended a range of potential mutagenic activity of pol  to solid tumors where 
somatic mutations produced by pol  are likely to be associated with the other factors, including 
exogenous exposures, UV radiation or alcohol consumption 31. 
We detected overlaps between pol  signatures with somatic mutations in various cancers. It is 
possible that the perturbed cell metabolism leads to the aberrant regulation of pol , for example, that 
what one expects in the completely disorganized environment of cell extracts (where the pol  
mutagenesis had beed inferred) 50, or in in vitro systems 22, while normal cells are well protected from its 
action 51. The error-prone action of misregulated pol  is expected to cause a substantial load of somatic 
mutations, which may be beneficial for cancer initiation and/or progression, for example, when TP53 is 
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mutated 27, 52. Another potential function of pol  in cancer cells could be the error-free or error-prone 
bypass of various DNA lesions. It was suggested in a recent paper 53 that NPM1 (nucleophosmin) 
regulates translesion DNA synthesis (TLS) via an interaction with the catalytic core of pol η. NPM1 
deficiency causes a TLS defect due to the proteasomal degradation of pol η. The prevalent NPM1 
mutation (c+) leading in one-third of AML patients to NPM1 mislocalization results in a loss of pol η, 
which may explain why no significant excess of mutation in pol η motifs was found for acute myeloid 
leukemia (Table 2). These results hint at the complexity of regulation of pol η in cancer cells and provide 
an explanation of why pol η mutational signatures are found only in some cancer types/subtypes.  
It was suggested that, in both normal and cancer skin cells, a significantly increased frequency of 
UVB-induced transition mutations at YCG motifs could be explained by the participation of pol  35. 
Taking into account the high frequency of mutations in TC dinucleotides, it is tempting to speculate that 
mutagenesis of YCG motifs is caused by the error-prone synthesis by pol  on methylated cytosine in 
TCG/CCG sequences (with or without neighboring photoproducts) (Figure 1). Thus, the error-prone 
synthesis in YCG motif might be an additional mechanism of demethylation, by pol  misincorporating A 
instead of G in various types of cancer cell. The evidence for that comes from the observed negative 
correlation between the excess of somatic mutations associated with AID and pol  mutable motifs in 
various types of cancer (Figure 2). However, this hypothesis requires further experimental validation and 
would require analysis of methylated templates using in vitro pol  mutagenesis systems. The analysis of 
mammalian model species and cell cultures might also provide the means to test this hypothesis. 
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Materials and Methods 
Analysis of somatic mutations 
DNA sequences surrounding the mutated nucleotide represent the mutation context. We 
compared the frequencies of known mutable motifs for somatic mutations with the frequencies of these 
motifs in the vicinity of the mutated nucleotides. Specifically, for each base substitution, the 120 bp 
sequence centered around the mutation was extracted (the DNA neighborhood). We used only the 
nucleotides immediately surrounding the mutations because DNA pol  is thought to scan a limited 
length of DNA to mutate nucleotides in a preferred motif 36, 54. This approach does not exclude any given 
region of the genome in general, but rather uses the areas within each sample where mutagenesis has 
happened (taking into account the variability in mutation rates across the human genome), and then 
evaluates whether the mutagenesis in this sample was enriched for DNA pol  motifs 36, 54. This 
approach was thoroughly tested and its high accuracy demonstrated 36. The frequencies of mutable 
motifs in the locations of somatic mutations was compared to the frequencies of the same motifs in the 
DNA neighborhood (Figure 3) using Fisher’s exact test (2 x 2 table, 2-tail test) as previously described 36, 
54 (for details see Figure 3). 
The exome sequencing data of somatic mutations in normal skin cells were obtained from 20. 
Somatic mutation data from the ICGC and TCGA cancer genome projects were extracted from the 
Sanger COSMIC Whole Genome Project v75 http://cancer-beta.sanger.ac.uk/cosmic. The tissues and 
cancer types were defined according to primary tumor site and cancer genome sequencing projects. 
Somatic mutations in various normal tissues were from Yadav et al. 43.  
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Power analysis of mutations in normal tissues 
We compared the magnitude of the difference between the fraction of mutations observed in 
the mutable motif and the fraction of motifs in the surrounding region (effect size) for somatic 
mutations in normal tissues. For the purpose of this comparison (power analysis), we used a sampling 
procedure that was repeated 1,000 times. Each sample of all available somatic mutations from cancer 
cells (where a significant excess of somatic mutations in WA/TW motifs was observed, the last row in 
the Table 2) had a size equal to that for normal tissues (552 somatic mutations, the last row in the 
Supplementary Table 1). Analysis of the difference between the fractions showed that the difference for 
normal mutations was smaller for 99.1% of cancer samples. Thus, the observed effect size 
(Supplementary Table 1) is likely to reflect the biological properties of these samples and is unlikely to 
result from the small sample size, at least for somatic mutations from normal tissues. 
 
Expression analysis of the POLH gene 
 For the POLH gene expression analysis, the normalized version of the RSEM (Broad Institute 
TCGA Genome Data Analysis Center, 2016, Analysis-ready standardized TCGA data from Broad GDAC 
Firehose 2016_01_28 run. Broad Institute of MIT and Harvard Dataset 
http://doi.org/10.7908/C11G0KM9) was used to analyze the TCGA RNA-Seq datasets from the Broad 
Genome Data Analysis Center. For each TCGA cohort (Supplementary Figure 1), the low and upper 
bounds, median, outliers, and first and third quartiles were retrieved via the FireBrowse RESTful API 
(http://firebrowse.org/api-docs/) for the tumor and the corresponding normal (when available) tissue 
samples. 
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Legends to Figures 
 
Figure 1. Frequency of tandem double (blue) and single mutations (red) in various dinucleotides. The 
Fnorm is a normalized frequency of double or single mutations (the number of mutations in 
dinucleotides XX multiplied by 1000 and divided by the number of dinucleotides XX in the DNA 
neighborhood).
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 Figure 2. Comparison of excess of somatic mutations associated with AID and pol  mutable motifs in 
various types of cancer. The excess of mutations in motifs was calculated using the ratio Fm/Fs, where 
Fm is the fraction of tandem somatic mutations (both positions are used for this analysis) observed in 
the studied mutable motif (the number of mutated motifs divided by the number of mutations), and Fs 
is the frequency of the motif in the DNA context of somatic mutations (the number of motif positions 
divided by the total number of all un-mutated positions in surrounding regions). Linear correlation 
coefficient is –0.44 (P = 0.044, one-tail test). The regression line is shown in black.
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 Figure 3. Statistical analysis of mutable motifs in sites of somatic mutations and surrounding regions. 
The excess of mutations in motifs was calculated using the ratio Fm/Fs, where Fm is the fraction of 
somatic mutations observed in the given mutable motif (the number of mutated motifs divided by the 
number of mutations), and Fs is the frequency of the motif in the DNA neighborhood of somatic 
mutations (the number of motif positions divided by the total number of all un-mutated positions in the 
120 bp window).
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Table 1. Association between DNA polymerase  mutable motifs (WA/TW)* and the DNA sequence 
context of somatic mutations in normal and cancer skin cells 
Mutable motif Fraction of mutations 
observed in the mutable 
motif (Fm) vs. Fraction of 
motifs in surrounding regions 
(Fs) 
Excess of 
mutations in 
the motif 
P-value, Fisher’s 
exact test ** 
Normal skin cells 
TC/GA and CT/AG 0.542. vs. 0.45 1.2 <10-10 
WA/TW 0.435 vs. 0.424 1.03 NS 
Skin cancer (the Sanger COSMIC Whole Genome Project) 
TC/GA and CT/AG 0.502 vs. 0.461 1.09 <10-10 
WA/TW 0.593 vs. 0.432 1.37 <10-10 
Skin cancer subtypes: skin cutaneous melanoma 
TC/GA and CT/AG 0.7 vs. 0.476 1.47 <10-10 
WA/TW 0.6 vs. 0.422 1.42 <10-10 
Skin cancer subtypes: skin adenocarcinoma 
TC/GA and CT/AG 0.406 vs. 0.427 0.95 NS 
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WA/TW 0.28 vs. 0.35 0.80 NS 
* The correlation was measured using Fisher’s exact test. Mutable positions in consensus sequences are 
underlined (W = A or T). The excess of mutations in motifs was calculated using the ratio Fm/Fs, where 
Fm is the fraction of somatic mutations observed in the given mutable motif (the number of mutated 
motifs divided by the number of mutations), and Fs is the frequency of the motif in the DNA 
neighborhood of somatic mutations (the number of motif positions divided by the total number of all 
un-mutated positions in the 120 bp window).  
** NS, no significant excess 
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Table 2. Preferential mutability of DNA polymerase  mutable motifs (WA/TW) in various cancers (single 
mutations from Whole Genomes and Whole Exomes, the Sanger COSMIC Whole Genome Project) 
Tissue Fraction of 
mutations observed 
in the mutable motif 
(total number of 
sites) 
Fraction of motifs in 
surrounding regions 
(total number of 
sites) 
Excess of 
mutations 
in the 
motif 
P-value, 
Fisher’s 
exact test* 
Blood 0.328 
(8,269) 
0.372 
(437,552) 
0.88 NS 
Chronic lymphocytic 
leukemia 
0.529 
(412) 
0.435 
(23,680) 
1.22 0.00009 
Acute myeloid 
leukemia 
0.29 
(6,727) 
0.351 
(348,871) 
0.83 NS 
GCB lymphomas 0.49 
(1,070) 
0.43 
(61,426) 
1.44 0.00003 
Bladder 0.468 
(5,952) 
0.426 
(339,359) 
1.1 <10-10 
Breast 0.453 0.428 1.06 <10-10 
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(18,453) (1,068,627) 
Cervix 0.499 
(3,193) 
0.448 
(186,165) 
1.11 <10-10 
Colon 0.466 
(45,103) 
0.43 
(2,595,315) 
1.08 <10-10 
Kidney 0.482 
(19,290) 
0.424 
(1,113,567) 
1.14 <10-10 
Liver 0.424 
(44,028) 
0.426 
(2,520,549) 
1.0 NS 
Lung 0.419 
(45,264) 
0.422 
(2,592,238) 
0.99 NS 
Ovary 0.441 
(8,114) 
0.423 
(461,545) 
1.03 0.0006 
Pancreas 0.482 
(9,394) 
0.427 
(535,889) 
1.13 <10-10 
Prostate 0.493 
(13,036) 
0.43 
(775,226) 
1.15 <10-10 
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Rectum 0.537 
(8,213) 
0.441 
(482,509) 
1.22 <10-10 
Skin 0.593 
(26,859) 
0.430 
(1,541,263) 
1.38 <10-10 
Stomach 0.504 
(50,212) 
0.431 
(2,897,221) 
1.17 <10-10 
Uterus 0.440 
(55,999) 
0.438 
(3,212,849) 
1.01 NS 
Tissue types with significant correlation (taking into account the Bonferroni correction for multiple tests) 
between the motif and somatic mutations are underlined. The excess of mutations in motifs was 
calculated using the ratio Fm/Fs, where Fm is the fraction of somatic mutations observed in the studied 
mutable motif (the number of mutated motifs divided by the number of mutations), and Fs is the 
frequency of the motif in the DNA context of somatic mutations (the number of motif positions divided 
by the total number of all un-mutated positions in surrounding regions). 
* Absence of significant excess of mutations in WA/TW (NS, no significant excess) suggests that there is 
no connection between mutagenesis and WA/TW motifs. 
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Table 3. Analysis of tandem somatic mutations in DNA polymerase  mutable motifs (WA/TW) in various 
cancers (Whole Genomes and Whole Exomes, the Sanger COSMIC Whole Genome Project) 
Tissue Fraction of mutations 
observed in the 
mutable motif (total 
number of sites) 
Fraction of motifs in 
surrounding regions 
(total number of sites) 
Excess of 
mutations 
in the 
motif 
P-value, 
Fisher’s 
exact test* 
Cervix 0.66 
(9) 
0.444 
(960) 
1.49 NS 
Colon 0.8 
(5) 
0.4 
(558) 
2. NS 
Kidney 0.571 
(7) 
0.286 
(766) 
2. NS 
Lung 1 
(13) 
0.39 
(1,322) 
2.6 5.310-6 
Ovary 0.944 
(18) 
0.167 
(1,806) 
5.65 4.710-6 
Pancreas 1 
(8) 
0.547 
(1,032) 
1.83 NS 
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Rectum 1 
(3) 
0.244 
(262) 
4.1 NS 
Skin 0.847 
(59) 
0.576 
(6,953) 
1.47 610-8 
All somatic 
mutations 
0.858 
(134) 
0.47 
(15,097) 
1.83 <10-10 
Tissue types with significant correlation (taking into account the Bonferroni correction for multiple tests) 
between the motif and somatic mutations are underlined. The excess of tandem mutations in motifs 
was calculated using the ratio Fm/Fs, where Fm is the fraction of tandem somatic mutations (both 
positions are used for this analysis) observed in the studied mutable motif (the number of mutated 
motifs divided by the number of tandem mutations), and Fs is the frequency of the motif in the DNA 
context of tandem somatic mutations (the number of motif positions divided by the total number of all 
un-mutated positions in surrounding regions). 
* Absence of significant excess of mutations in WA/TW (NS, no significant excess) suggests that there is 
no association between mutagenesis and WA/TW motifs. 
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